{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:14:13Z","timestamp":1786796053762,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.xcrm.2023.101227","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:49:45Z","timestamp":1697554185000},"page":"101227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing"],"prefix":"10.1016","volume":"4","author":[{"given":"Chuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1671-5291","authenticated-orcid":false,"given":"Scott M.","family":"Leighow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"McIlroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengrou","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kady A.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Abello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.101227_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J.\u00a0Health Econ."},{"key":"10.1016\/j.xcrm.2023.101227_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2023.101227_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2023.101227_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drudis.2018.06.012","article-title":"Renovation as innovation: is repurposing the future of drug discovery research?","volume":"24","author":"Neuberger","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xcrm.2023.101227_bib5","article-title":"Phase III trial failures: costly, but preventable","author":"Grignolo","year":"2016","journal-title":"Appl. Clin. Trials"},{"key":"10.1016\/j.xcrm.2023.101227_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2018.00006","article-title":"Three-Dimensional in\u00a0Vitro Cell Culture Models in Drug Discovery and Drug Repositioning","volume":"9","author":"Langhans","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2023.101227_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/laban.1224","article-title":"Introducing Therioepistemology: the study of how knowledge is gained from animal research","volume":"46","author":"Garner","year":"2017","journal-title":"Lab Anim."},{"key":"10.1016\/j.xcrm.2023.101227_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide\u00a0\u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"10.1016\/j.xcrm.2023.101227_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.101227_bib10","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101227_bib11","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/cncr.28696","article-title":"Patient-derived xenografts for individualized care in advanced sarcoma","volume":"120","author":"Stebbing","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2023.101227_bib12","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","article-title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","volume":"28","author":"Izumchenko","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2023.101227_bib13","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101227_bib14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Gitelman","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2023.101227_bib15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2023.101227_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2012.06.028","article-title":"Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva","volume":"127","author":"Horowitz","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.xcrm.2023.101227_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoncol.2015.4364","article-title":"Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial","volume":"2","author":"William","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2023.101227_bib18","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.18632\/oncotarget.12673","article-title":"Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays","volume":"8","author":"Eastman","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2023.101227_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2011.03907.x","article-title":"What is a relevant statin concentration in cell experiments claiming pleiotropic effects?","volume":"72","author":"Bj\u00f6rkhem-Bergman","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2023.101227_bib20","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.1021\/jm5007935","article-title":"Rational use of plasma protein and tissue binding data in drug design","volume":"57","author":"Liu","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.xcrm.2023.101227_bib21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in\u00a0vivo efficacy: Misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2023.101227_bib22","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.bmcl.2004.01.103","article-title":"A simple method for predicting serum protein binding of compounds from IC(50) shift analysis for in\u00a0vitro assays","volume":"14","author":"Rusnak","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.xcrm.2023.101227_bib23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2023.101227_bib24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.xcrm.2023.101227_bib25","first-page":"469","volume":"27","author":"Redaelli","year":"2016"},{"key":"10.1016\/j.xcrm.2023.101227_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cell.2016.01.045","article-title":"Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution","volume":"165","author":"Zhao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2023.101227_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2023.101227_bib28","series-title":"Avapritinib versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study","author":"Kang","year":"2021"},{"key":"10.1016\/j.xcrm.2023.101227_bib29","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","article-title":"Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate","volume":"12","author":"Wardelmann","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101227_bib30","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","article-title":"Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours","volume":"120","author":"Serrano","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2023.101227_bib31","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101227_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xcrm.2023.101227_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2023.101227_bib34","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.xcrm.2023.101227_bib35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2901-9","article-title":"Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids","volume":"589","author":"Han","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2023.101227_bib36","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1158\/0008-5472.CAN-11-1014","article-title":"Bcl-2 Family Genetic Profiling Reveals Microenvironment-Specific Determinants of Chemotherapeutic Response","volume":"71","author":"Pritchard","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101227_bib37","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome\u2013Positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101227_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":"Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2023.101227_bib39","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101227_bib40","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101227_bib41","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/bjc.2011.332","article-title":"Erlotinib \u2018dosing-to-rash\u2019: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer","volume":"105","author":"Mita","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2023.101227_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2016.01.005","article-title":"Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer","volume":"93","author":"Hirose","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101227_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.xcrm.2023.101227_bib44","unstructured":"Takeda Pharmaceuticals ALUNBRIG (Brigatinib) FDA Label."},{"key":"10.1016\/j.xcrm.2023.101227_bib45","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2017.1401064","article-title":"Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer","volume":"13","author":"Rossi","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.xcrm.2023.101227_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101227_bib47","article-title":"Combination of white blood cell count at presentation with molecular response at 3\u00a0months better predicts deep molecular responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"95","author":"Qin","year":"2016","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.xcrm.2023.101227_bib48","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1038\/sj.onc.1208796","article-title":"Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2023.101227_bib49","first-page":"625","article-title":"\u03b11 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin. Cancer Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:11:43Z","timestamp":1715047903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123004044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2666379123004044"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101227","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101227"}}